A federal district court has held that design defect claims against a brand pharmaceutical manufacturer are preempted by federal law. Booker v. Johnson & Johnson, No. 3:12 oe 40000, 2014 WL 5113305 (N.D. Ohio
Oct. 10, 2014).
Setting the Stage – Mutual v. Bartlett
In 2013, the United States Supreme Court held that federal law preempts failure-to-warn design defect claims against generic drug manufacturers. Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013). The Supreme Court based its Bartlett decision in part on PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011), which held that federal law prohibited generic manufacturers from implementing unilateral label changes, and therefore preempted state-law requirements (through statutes or juries) that a drug company strengthen its warnings. Of particular relevance, the Supreme Court also stated in Bartlett that the drug at issue—a single-molecule drug—was “chemically incapable of being redesigned.” 133 S. Ct. at 2475. However, the Supreme Court fell short of holding that design defect claims against brand manufacturers were preempted, setting the stage for the Booker case, decided last month.
Booker arose out of the Ortho Evra MDL pending in the Northern District of Ohio. The plaintiff sued on behalf of her deceased daughter, who allegedly died from a pulmonary embolism after using Ortho Evra, a branded birth control patch.
Defendants moved for summary judgment on plaintiff’s design and manufacturing defect claims, subsequent to the court’s ruling that the package insert adequately warned of increased risk of blood clots and pulmonary embolism.
Design Defect Under Georgia Law
The court evaluated the alleged design defect under Georgia law. Like many states, Georgia follows the Restatement (Second) of Torts, section 402A, comment k. Under comment k, pharmaceutical products, “properly prepared, and accompanied by proper directions and warnings, [are] not defective, nor [are they] unreasonably dangerous.” To assert comment k as an affirmative defense under Georgia law, the defendant must show that “(1) the product is properly manufactured and contains adequate warnings; (2) its benefits justify its risks; and (3) the product was at the time of the manufacture and distribution incapable of being made more safe.”
Because the court had already determined the warnings were adequate as a matter of law, the only remaining issues were whether the benefits of the product outweighed its risks and whether the product was incapable of being made more safe.
Alternative Design Prohibited by Federal Law
In weighing the risks against the benefits of any design, Georgia law focuses on “whether an alternative design would have made the product safer than the original design and was a marketable reality and technologically feasible.” The Booker court found that plaintiff made a prima facie case of design defect because she alleged that birth control pills and intrauterine devices were two alternative designs available at the time decedent was prescribed Ortho Evra. The court then stated clearly that under Georgia law, defendants’ motion for summary judgment for design defect would be denied.
But the court went on to grant the motion because of preemption. The court relied primarily on the language from Bartlett that single-molecule drugs are incapable of redesign: “state-law design defect claims . . . that place a duty on manufacturers to render a drug safer by either altering its composition or altering its labeling are in conflict with federal laws that prohibit manufacturers from unilaterally altering drug composition or labeling.” The Bartlett case discussed only generic drugs and the inability of generic drug manufacturers to change the chemical composition of their products due to the sameness requirements of the Hatch-Waxman Amendments. The Supreme Court also found that a “simple” drug is “chemically incapable of being redesigned.” Although technically dicta, this language was correctly interpreted by the Booker court as applying with equal weight to any pharmaceutical manufacturer, whether brand or generic. In doing so, the court applied Bartlett to preempt design defect claims against brand manufacturers—even when those claims do not sound in failure to warn.
Impact of Booker
The reasoning underlying the Booker court’s holding would extend to all single-molecule drugs, which comprise virtually all prescription drugs that are not biologics. Any molecule constituting an active pharmaceutical ingredient could not be “redesigned” and still be an FDA-approved drug. If other courts follow suit, pharmaceutical manufacturers would finally be able to rely on FDA approval as a defense to design defect claims.
 Defendants had successfully moved for summary judgment on the failure-to-warn claim, among others. Defendants had also unsuccessfully moved for judgment on the pleadings on the design and manufacturing defect claims, and re-raised those arguments here on a motion for summary judgment.
 Booker, 2014 WL 5113305, at *3 (quoting Bryant v. Hoffman-La Roche, Inc., 585 S.E.2d 723, 728 (Ga. Ct. App. 2003)).
 Id. (quoting Bryant, 585 S.E.2d at 728).
 Id. (quoting Banks v. BCI Ams., 450 S.E.2d 674 (Ga. 1994)).
 Id. (quoting Bartlett, 133 S. Ct. at 2479).